The neonatal fragment crystallizable (Fc) receptor (FcRn) plays a crucial role in the recycling mechanism of IgG and albumin in the circulation. Targeting FcRn has been explored as a potential therapeutic strategy for immunomodulation. By inhibiting FcRn, researchers aim to modulate the immune response and prevent or treat various diseases. This approach has shown promise in preclinical studies, but its safety and efficacy in humans remain to be determined. Further research is needed to fully understand the benefits and risks of targeting FcRn for immunomodulation.